## **Supporting Information**

## Sharma et al. 10.1073/pnas.1107087108

## **SI Materials and Methods**

**Flow Cytometry.** The antibodies to CD8 (53-6.7), CD4 (RM4-5), CD62 ligand (CD62L) (MEL-14), CD44 (IM7), IFN $\gamma$ , TNF $\alpha$ , IL-2, and CD103 (2E7) were purchased from BD Bioscience. Phycoerytherin- and allophycocyanin-conjugated Tim-3 antibodies were purchased from R&D Systems. Intranuclear FoxP3 staining (E-Bioscience) was performed according to the instructions. Cell suspensions were blocked with anti-mouse CD16/32 and then incubated with specific antibodies or isotypes for 30 min at 4 °C. The antibody-stained cells were acquired with a FACS Calibur (BD Biosciences) and the data were analyzed using the FlowJo software (Tree Star).

Adoptive Transfers. Splenocytes from WT or G9KO (both Thy1.2)  $\times$ 31 immune mice were enriched (Miltenyi Biotech kit) for CD8 T cells and then titrated for 10<sup>4</sup> NPtet<sup>+</sup> CD8 T cells and transferred into Thy1.1 C57BL/6 animals. Alternatively 10<sup>4</sup> NPtet<sup>+</sup> CD8 T from B6Thy1.1 ( $\times$ 31 immune) mice were transferred into Thy1.2 C57BL/6 WT or G9KO animals. At 24 h posttransfer, recipient animals were infected with 8,000 EID<sub>50</sub> pfu of IAV PR8. At 8 d postchallenge, CD8 T-cell analysis was performed.



**Fig. S1.** Activated cells express Tim-3 and Gal-9 levels are up-regulated in lungs after IAV infection. At different time points after infection, BAL and spleen cells (n = 3) isolated at each time point were analyzed flow cytometrically for Tim-3 expression on IAV-specific CD8 T cells. BAL samples from three mice were pooled. (A) FACS plots showing Tim-3<sup>+</sup>IFN $\gamma^+$  CD8 T cells at day 10 p.i. in the BAL fluid of WT animals. (B) Coexpression of Tim-3 (*Upper*) and D<sup>b</sup>NPtet<sup>+</sup> (*Lower*) with CD44 and CD62L in BAL of WT mice at day 8 p.i. is shown by representative FACS plots. (C) Immunoblots showing Gal-9 expression in the lung homogenates from naïve and IAV-infected mice at different time points post infection. (D) Gal-9 concentrations as measured by sandwich ELISA using anti–Gal-9 mAb in the lung homogenates is shown. Numbers in the quadrants indicate percent of each subset. Data are representative of three independent experiments.



**Fig. 52.** Galectin-9 induces apoptosis of IAV NP tetramer-specific and Tim-3<sup>+</sup> CD8 T cells in vitro. Ex vivo apoptosis assay was performed with splenocytes isolated at 10 days postinfection from IAV-infected animals as described previously (1). Briefly splenocytes were incubated for 5 h with varying concentrations of galectin-9 in the absence or presence of  $\alpha$ -lactose. The experiments were repeated multiple times with similar results. (A) Representative FACS plots showing the expression of Tim-3 and annexin-V on gated CD8 T cells under indicated incubation conditions. (*B*) Representative FACS plots showing the expression of Tim-3 and annexin-V on gated CD8 T cells under indicated incubation conditions. (*C*) Bar diagram shows the percentage of Tim-3<sup>+</sup> CD8 T cells as calculated from *A* (with triplicate wells). (*D*) Bar diagram shows the percentage of NPtet<sup>+</sup> CD8 T cells as calculated from *B*. Statistical analysis was done by two-way ANOVA with Bonferroni post hoc settings.

1. Sehrawat S, et al. (2010) Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 6:e1000882.



**Fig. S3.** Gating strategy to depict preferential apoptosis of Tim-3<sup>+</sup> CD8T cells upon Galectin-9 exposure. (*A*) Representative FACS plots showing gated CD8T cells from the cultures in an ex vivo apoptosis assay. (*B*) Tim-3<sup>+</sup> and Tim-3<sup>-</sup> CD8T cells are shown by representative FACS plot. (*C*) FACS plots depicting Tim-3<sup>+</sup> annexinV<sup>+</sup> (*Upper*) and Tim-3<sup>-</sup> annexin V<sup>+</sup> CD8 T cells (*Lower*). (*D*) Representative FACS plots showing the expression of annexin-V on gated Tim-3<sup>+</sup> CD8 T cells under indicated incubation conditions. (*E*) Representative FACS plots showing the expression of annexin-V on gated Tim-3<sup>-</sup> CD8 T cells under indicated incubation conditions.



**Fig. 54.** Characterization of  $CD4^+FoxP3^+$  regulatory T cells from WT and G9KO mice. C57BL/6 and G9KO animals were infected intranasally with 5,000 EID<sub>50</sub>. BAL samples from three mice were pooled and spleens from individual mice were stained for FoxP3. Representative FACS plots show the frequencies of FoxP3<sup>+</sup> Tregs in the BAL (*A*) and spleens (*D*) of WT and G9KO animals at day 10 p.i. The kinetics of Treg frequencies at indicated timepoints p.i. (*B*) and their absolute numbers at day 10 p.i. (*C*) in the BAL fluid of WT and G9KO are shown. Histograms show the expression of Tim-3 (*E*), CD103 (*F*), and CD44 (WT, light line) and (G9KO, dark line) (*G*) on FoxP3<sup>+</sup> Tregs isolated from the spleens of WT and G9KO animals at day 10 p.i.



**Fig. S5.** Outcome of infection with IAV HK×31. WT mice were inoculated with IAV HK×31 ( $10^8$ ,  $10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$  EID<sub>50</sub> or PBS). (A) Body weight of WT mice after infection was determined daily and expressed as the percentage of the body weight lost following infection. (*B*) Percentage of body weight-loss comparison between the WT and G9KO mice infected with 5,000 EID<sub>50</sub> intranasally (*i*/n) over a period of 10 d. (*C*) Percentage of body weight-loss comparison between WT and G9KO mice infected with  $5 \times 10^7$  EID<sub>50</sub> i/n over a period of 10 d. The data are representative of five to six mice per group.



**Fig. S6.** Cells obtained from bronchoalveolar lavage (BAL) were stained for CD45<sup>+</sup> (pan leukocyte marker) and CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> (neutrophils) and FACS analysis performed at day 3 (A and B) and day 7 (D and E) in WT and G9KO mice. Bar graphs representing % CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup> (neutrophils) at day 3 p.i. (C) and day 7 p.i. (F) is shown. Experiments were repeated multiple times and the data are representative of pooled BAL samples from three mice. Statistical analysis was done by Student's t test and error bars represent SEM.



		%Parench yma involved	PMN# (Average/40x field)	Remarks
бэко	Day 3	0%	0	Normal lung, no recognizable pathological changes
	Day 7	1-4	2-4	Mild multifocal broncho-interstitial pneumonia
	Day 9	21-30%	4-30	Moderate to marked multifocal broncho- interstitial pneumonia, primarily mononuclear lymphocytic infiltrates with lesser number of macrophages,scattered parenchymal/infilterative individual cell necrosis and degeneration
	Day 3	4%	0-5	Mild, regionally limited, multifocal broncho- interstitial pneumonia
	Day 7	4-5%	5-7	Mild multifocal broncho-interstitial pneumonia
	Day 9	10-20%	2-50	Moderate multifocal broncho-interstitial pneumonia, primarily mononuclear lymphocytic infiltrates with lesser numbers of macrophages, occasional foci of intense neutrophilic infiltrates, moderate scattere parenchymal/infiltrative individual cell necrosis/apoptosis

**Fig. 57.** Histopathology. The lungs of mice infected with 5,000 or  $5 \times 10^7$  EID<sub>50</sub> of virus were harvested at indicated timepoints postinfection, washed in PBS, fixed in 10% neutral buffered formalin, and embedded in paraffin wax. Sections (5 mm) were stained with hematoxylin and eosin and microscopically reviewed. H&E sections from WT (*A*) and G9KO (*B*) animals infected with 5,000 EID<sub>50</sub> of IAV ×31 at day 9 p.i. are shown. Representative H&E sections from WT (*C*) and G9KO (*D*) animals infected with 5 × 10<sup>7</sup> EID<sub>50</sub> of IAV ×31 at day 10 p.i. are shown. The section blocks in the *Upper Right* corner represent the 40× magnification. The overall lung readouts (*n* = 3 mice at each timepoint/group infected with ×31 5,000 EID<sub>50</sub>) are indicated as a table (*E*).



**Fig. S8.** Adoptive transfer of memory CD8 T cells. Splenocytes from either WT or G9KO (both Thy1.2) HK×31 immune mice (mice were held for at least 1 mo following infection with IAV HK×31 i/n) were enriched for CD8T cells using Miltenyi Biotech (CD8T cell isolation) kit. Around 93–94% pure CD8T cells were obtained in the enriched CD8T cell population. The enriched CD8T cells were then titrated for equal number of NP tetramer-specific CD8T cells and  $1 \times 10^4$  antigen-specific CD8T cells were transferred in B6 Thy1.1 mice (n = 4). Alternatively splenocytes from B6 Thy1.1 HK×31 immune mice (mice were held for at least 1 mo following infection with IAV HK×31 i/n) were enriched for CD8T, and equal number of NP tetramer-specific CD8T ( $1 \times 10^4$ ) cells were transferred in B6 Thy1.1 mice (n = 4). Alternatively splenocytes from B6 Thy1.1 HK×31 immune mice (mice were held for at least 1 mo following infection with IAV HK×31 i/n) were enriched for CD8T, and equal number of NP tetramer-specific CD8T ( $1 \times 10^4$ ) cells were transferred in WT or G9KO mice (n = 4). Twenty-four hours posttransfer, the recipients were challenged with 8,000 ElD<sub>50</sub> of heterologous IAV (PR8). (A) Diagrammatic depiction of the scheme for adoptive transfer experiments. (B) Representative FACS plots for enriched CD8T cell population. FACS plots show the frequencies of donor Thy1.2<sup>+</sup>CD8<sup>+</sup> (C, *Upper*) and NPtet<sup>+</sup> Thy1.2<sup>+</sup> CD8<sup>+</sup> (C, *Lower*) WT or G9KO cells in the MLN (C), and spleen (D) of Thy1.1 animals at 8 d p.i. Absolute numbers of the donor NPtet<sup>+</sup>Thy1.2<sup>+</sup>CD8<sup>+</sup> T cells of WT or G9KO in the MLN (E) and spleens (F) of the recipients are shown. Absolute numbers of the donor NPtet<sup>+</sup>Thy1.1<sup>+</sup>CD8<sup>+</sup>T WT or G9KO cells in the MLN (G) and spleens (H) of the recipients are shown. The experiments were repeated two times. Statistical analysis was done by Student's t test and the error bars represent SEM. (I) Representative histograms showing CD62L expression by NPtet<sup>+</sup> CD8 T cells in the MLNs of WT and G9KO animals at d



**Fig. S9.** Administration of Tim-3 fusion protein in mice at later stages post IAV infection enhances the magnitude and quality of IAV-specific CD8 T cells responses. IAV-infected C57BL/6 animals were treated with 100  $\mu$ g of Tim-3 fusion protein (per mouse) from day 4 postinfection at alternate days until day 9 p.i., and 12 h after the last treatment the animals were killed. Frequencies of NPtet<sup>+</sup> CD8 T cells (*A*) isolated from the BAL (*Upper*) and spleen (*Lower*) of Tim-3 fusion protein-treated and control animals are shown. (*B*) Absolute numbers of NPtet<sup>+</sup>, IFN $\gamma^+$ TNF $\alpha^+$  CD8 T cells in the BAL. (C) MFI of IFN $\gamma$  in Tim-3 Ig and control animals. (*D*) Representative FACS plots showing frequencies of CD3<sup>-</sup>B220<sup>+</sup>PNA<sup>+</sup>FAS<sup>+</sup> germinal center B cells in the mediastinal lymph node (MLN) of Tim-3 Ig and control Ig-treated mice at day 10 p.i. Data are representative of two independent experiments with three mice per group. Error bars represent SEM.